Current Front-Line Targeted Treatments in Ph+ ALL

Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

EP: 1.Overview of Characteristics Unique to Ph+ ALL

EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL

EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

EP: 4.Screening and Diagnosing of Ph+ ALL in Adults

EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

Now Viewing

EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL

EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients

EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients

EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care

EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL

EP: 11.Disparities in Access to Care for Ph+ ALL patients

EP: 12.The Future of Ph+ ALL Treatments

EP: 13.Concluding Thoughts on Ph+ ALL Treatment

Related Videos

Related Content

Advertisement

December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 29th 2024

sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

AJMC Contributor

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 29th 2024

5 Things About Diabetic Eye Disease

Laura Joszt, MA

November is Diabetic Eye Disease Awareness Month. Diabetes is the leading cause of preventable blindness in the US. Here is a look at recent research related to diabetic eye diseases.

November 28th 2024

European Commission Approves Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

Caroline Seymour

The European Commission has approved mirvetuximab soravtansine for select patients with pretreated folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer.

Related Content

Advertisement

December 2nd 2024

Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC

Maggie L. Shaw

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi

Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.

November 29th 2024

sGFAP May Predict Progression Independent of Relapse in BCDT-Treated MS

AJMC Contributor

The findings show that increases in serum glial fibrillary acidic protein throughout B-cell depletion therapy are associated with disability worsening despite not relapsing—known as progression independent of relapse activity.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

November 29th 2024

5 Things About Diabetic Eye Disease

Laura Joszt, MA

November is Diabetic Eye Disease Awareness Month. Diabetes is the leading cause of preventable blindness in the US. Here is a look at recent research related to diabetic eye diseases.

November 28th 2024

European Commission Approves Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

Caroline Seymour

The European Commission has approved mirvetuximab soravtansine for select patients with pretreated folate receptor–alpha (FRα)-positive, platinum-resistant ovarian cancer.